Changhai Hospital
Clinical trials sponsored by Changhai Hospital, explained in plain language.
-
Immune cell therapy takes on kidney disease
Disease control Recruiting nowThis early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug aims to stop Chemo-Induced bleeding risk in stomach and colon cancers
Disease control Recruiting nowThis phase 2 trial is testing whether the drug hetrombopag can prevent chemotherapy-induced thrombocytopenia (low platelet counts) in people with gastrointestinal tumors. The study will enroll 40 patients who had low platelets in a previous chemo cycle. Participants take hetrombo…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Universal CAR-T cells take on lupus and more in early trial
Disease control Recruiting nowThis early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on pancreatic cancer in early trial
Disease control Recruiting nowThis early-stage study tests a new treatment called CAR-NK cells (CL-NK-003) in 9 people with advanced pancreatic cancer that has not responded to standard therapies. The main goal is to check safety and find the right dose. Researchers will also watch for signs that the treatmen…
Phase: PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Engineered immune cells take on kidney disease in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Bladder-Sparing hope: immune combo targets tough bladder cancer
Disease control Recruiting nowThis study tests whether adding an immunotherapy drug (toripalimab) to standard BCG therapy can help people with high-risk bladder cancer avoid bladder removal. About 31 participants will receive the combination after surgery. The main goal is to see if the cancer disappears with…
Phase: PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Engineered immune cells take on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis trial tests a personalized cell therapy for advanced pancreatic cancer. Patients receive their own immune cells that have been engineered to recognize and attack cancer cells with a specific mutation (KRAS G12V). The study enrolls 30 people whose tumors carry this mutation a…
Phase: PHASE1, PHASE2 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Freeze, then boost: novel combo could spare bladders from removal
Disease control Recruiting nowThis study tests a new approach to treat high-risk bladder cancer without removing the bladder. Doctors will first remove the tumor through the urethra, then freeze the tumor base with a special balloon, followed by immunotherapy and low-dose chemotherapy. The goal is to see if t…
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Poop pills vs. pancreatitis: can gut transplants stop deadly infections?
Disease control Recruiting nowThis study tests whether transplanting healthy gut bacteria (FMT) can reduce infections in people with moderate to severe acute pancreatitis. 80 participants will receive either FMT or a placebo through a feeding tube for five days. The goal is to see if FMT lowers the risk of se…
Phase: NA • Sponsor: Changhai Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:29 UTC
-
AI reads CT scans to spot pancreatic cancer faster
Diagnosis Recruiting nowThis study tests an artificial intelligence (AI) system that analyzes contrast-enhanced CT scans to help diagnose and manage pancreatic diseases. The AI will classify patients into three groups: needing immediate treatment, close monitoring, or routine follow-up. Researchers will…
Sponsor: Changhai Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Poop pills may stop deadly infections in pancreatitis patients
Prevention Recruiting nowThis study tests whether fecal microbiota transplantation (FMT) — transferring gut bacteria from healthy donors — can prevent infections in people with moderately severe or severe acute pancreatitis. About 150 adults will receive either FMT liquid or a placebo through a feeding t…
Phase: NA • Sponsor: Changhai Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
New combo approach aims to stop pancreatitis after stone treatment
Prevention Recruiting nowThis study tests whether giving extra IV fluids along with a standard anti-inflammatory suppository can better prevent pancreatitis after a procedure to break up pancreatic stones. About 1250 adults with chronic pancreatitis will be randomly assigned to receive either the combina…
Phase: NA • Sponsor: Changhai Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:06 UTC
-
Could a Half-Dose of a common drug prevent a painful complication just as well?
Prevention Recruiting nowThis study compares a low dose (50 mg) versus the standard dose (100 mg) of indomethacin given rectally before ERCP to prevent post-procedure pancreatitis. About 1,366 adults undergoing ERCP will be randomly assigned to one of the two doses in a double-blind fashion. The goal is …
Phase: PHASE4 • Sponsor: Changhai Hospital • Aim: Prevention
Last updated Jun 27, 2026 07:57 UTC
-
New diet could simplify colonoscopy prep for IBD patients
Symptom relief Recruiting nowThis study tests whether a pre-packaged low-residue diet (Maifu Changqing®) helps people with inflammatory bowel disease (IBD) prepare for colonoscopy more comfortably and effectively. About 500 adults with IBD will be enrolled across multiple hospitals in China. The goal is to s…
Phase: NA • Sponsor: Changhai Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New diet could make colonoscopy prep less miserable for IBD patients
Symptom relief Recruiting nowThis study tests whether a pre-packaged low-residue nutrition formula (Maifu Changqing®) can improve bowel cleanliness and comfort during colonoscopy preparation for 1,000 adults with inflammatory bowel disease (IBD). Participants will be randomly assigned to receive either the s…
Phase: NA • Sponsor: Changhai Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
New study aims to improve colonoscopy prep for IBD patients
Knowledge-focused Recruiting nowThis study involves 1,000 adults with inflammatory bowel disease (IBD) who need a colonoscopy. Researchers want to see how well current bowel preparation methods work and what factors lead to poor preparation. The goal is to create a tool that predicts which patients might have t…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
New database aims to spot early stomach cancer signs
Knowledge-focused Recruiting nowThis study is gathering images from special cameras and CT scans, along with lab results, to create a database for early upper gastrointestinal cancers and precancerous conditions. About 500 adults who need certain procedures will take part. The goal is to help doctors better rec…
Sponsor: Changhai Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC